Arix co-leads $63 million Series B investment round for Imara

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF THE EU MARKET ABUSE REGULATION NO.596/2014

  • Arix co-leads a $63 million Series B investment in new portfolio company Imara
  • Arix commits $15.0 million (£11.3 million)[1] for 10% ownership stake
  • Arix expands breadth of portfolio with investment in sickle cell disease via a later-stage clinical asset in phase 2

LONDON, 18 March 2019: Arix Bioscience plc (“Arix”) (LSE: ARIX), a global healthcare and life science company supporting medical innovation, today announces it has invested in new portfolio company Imara, Inc. (“Imara”), a company dedicated to developing novel therapeutics for chronic treatment of Sickle Cell Disease (“SCD”) and other hemoglobinopathies.

Read more

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH